Galapagos NV (GLPG.AS)
EUR 23.54
(-2.08%)
EUR 23.54
(-2.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 203.73 Million EUR | -58.7% |
| 2022 | 493.2 Million EUR | 2.07% |
| 2021 | 483.21 Million EUR | 1159.36% |
| 2020 | -45.61 Million EUR | -110.92% |
| 2019 | 417.66 Million EUR | 1326.99% |
| 2018 | -34.04 Million EUR | 62.76% |
| 2017 | -91.41 Million EUR | -808.97% |
| 2016 | -10.05 Million EUR | 88.84% |
| 2015 | -90.15 Million EUR | -115.97% |
| 2014 | -41.74 Million EUR | -143.3% |
| 2013 | 96.4 Million EUR | 9.43% |
| 2012 | 88.09 Million EUR | 402.73% |
| 2011 | -29.09 Million EUR | -555.1% |
| 2010 | 6.39 Million EUR | -19.99% |
| 2009 | 7.99 Million EUR | -83.76% |
| 2008 | 49.2 Million EUR | 37.57% |
| 2007 | 35.77 Million EUR | 129.02% |
| 2006 | 15.61 Million EUR | 143.63% |
| 2005 | 6.41 Million EUR | -1.2% |
| 2004 | 6.48 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 59.83 Million EUR | -2.42% |
| 2024 Q2 | 61.31 Million EUR | 2.39% |
| 2024 Q1 | 59.88 Million EUR | 120.4% |
| 2023 Q2 | 145.68 Million EUR | -16.89% |
| 2023 FY | 203.71 Million EUR | -58.7% |
| 2023 Q1 | 175.29 Million EUR | 92.68% |
| 2023 Q4 | -293.55 Million EUR | -356.76% |
| 2023 Q3 | 114.32 Million EUR | -21.52% |
| 2022 Q3 | 133.81 Million EUR | -0.86% |
| 2022 Q1 | 133.43 Million EUR | -19.63% |
| 2022 Q2 | 134.97 Million EUR | 1.15% |
| 2022 Q4 | 90.97 Million EUR | -32.01% |
| 2022 FY | 493.2 Million EUR | 2.07% |
| 2021 Q4 | 166.01 Million EUR | 160.77% |
| 2021 FY | 483.21 Million EUR | 1159.36% |
| 2021 Q1 | 113.85 Million EUR | 776.07% |
| 2021 Q2 | 139.67 Million EUR | 22.68% |
| 2021 Q3 | 63.66 Million EUR | -54.42% |
| 2020 Q4 | 12.99 Million EUR | 3046.94% |
| 2020 FY | -45.61 Million EUR | -110.92% |
| 2020 Q3 | -441 Thousand EUR | 99.03% |
| 2020 Q2 | -45.51 Million EUR | -144.82% |
| 2020 Q1 | -18.59 Million EUR | -89.59% |
| 2019 Q2 | -35.63 Million EUR | 28.94% |
| 2019 FY | 417.66 Million EUR | 1326.99% |
| 2019 Q4 | -9.8 Million EUR | -101.91% |
| 2019 Q1 | -50.14 Million EUR | -428.6% |
| 2019 Q3 | 513.25 Million EUR | 1540.35% |
| 2018 FY | -34.04 Million EUR | 62.76% |
| 2018 Q2 | -32 Million EUR | -0.46% |
| 2018 Q3 | 14.56 Million EUR | 145.49% |
| 2018 Q1 | -31.85 Million EUR | -5.98% |
| 2018 Q4 | 15.26 Million EUR | 4.81% |
| 2017 Q3 | -29.36 Million EUR | -39.52% |
| 2017 FY | -91.41 Million EUR | -808.97% |
| 2017 Q2 | -21.05 Million EUR | -92.45% |
| 2017 Q1 | -10.93 Million EUR | -129.82% |
| 2017 Q4 | -30.06 Million EUR | -2.36% |
| 2016 Q4 | 36.67 Million EUR | 258.67% |
| 2016 Q2 | -5.91 Million EUR | 66.56% |
| 2016 FY | -10.05 Million EUR | 88.84% |
| 2016 Q1 | -17.69 Million EUR | 31.0% |
| 2016 Q3 | -23.11 Million EUR | -290.51% |
| 2015 Q4 | -25.64 Million EUR | 8.02% |
| 2015 Q1 | -16.77 Million EUR | -22.75% |
| 2015 FY | -90.15 Million EUR | -115.97% |
| 2015 Q3 | -27.88 Million EUR | -40.51% |
| 2015 Q2 | -19.84 Million EUR | -18.32% |
| 2014 Q1 | -3.87 Million EUR | -188.58% |
| 2014 FY | -41.74 Million EUR | -143.3% |
| 2014 Q4 | -13.66 Million EUR | -27.39% |
| 2014 Q3 | -10.72 Million EUR | -176.76% |
| 2014 Q2 | -3.87 Million EUR | 0.0% |
| 2013 Q3 | 4.37 Million EUR | -41.82% |
| 2013 Q4 | 4.37 Million EUR | 0.0% |
| 2013 Q2 | 7.51 Million EUR | 0.0% |
| 2013 Q1 | 7.51 Million EUR | 115.41% |
| 2013 FY | 96.4 Million EUR | 9.43% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | -48.8 Million EUR | -566.64% |
| 2012 FY | 88.09 Million EUR | 402.73% |
| 2012 Q3 | 10.45 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | -29.09 Million EUR | -555.1% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | 6.39 Million EUR | -19.99% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 7.99 Million EUR | -83.76% |
| 2008 FY | 49.2 Million EUR | 37.57% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | 35.77 Million EUR | 129.02% |
| 2006 FY | 15.61 Million EUR | 143.63% |
| 2005 FY | 6.41 Million EUR | -1.2% |
| 2004 FY | 6.48 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -32866.828% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -5105.289% |
| Adocia SA | 1.38 Million EUR | -14610.108% |
| Aelis Farma SA | 12.35 Million EUR | -1548.608% |
| Biophytis S.A. | -803 Thousand EUR | 25471.731% |
| Advicenne S.A. | 1.42 Million EUR | -14187.167% |
| genOway Société anonyme | 20.1 Million EUR | -913.588% |
| IntegraGen SA | 5.01 Million EUR | -3959.857% |
| Medesis Pharma S.A. | -2.66 Million EUR | 7745.506% |
| Neovacs S.A. | 29.31 Thousand EUR | -694909.211% |
| NFL Biosciences SA | -56.06 Thousand EUR | 363497.189% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -9363.207% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 14454.723% |
| Sensorion SA | 3.78 Million EUR | -5278.628% |
| Theranexus Société Anonyme | -4.63 Million EUR | 4492.081% |
| TME Pharma N.V. | -127 Thousand EUR | 160521.26% |
| Valbiotis SA | 2.66 Million EUR | -7536.244% |
| TheraVet SA | -530.79 Thousand EUR | 38482.919% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -15980.11% |
| argenx SE | 925.49 Million EUR | 77.986% |
| BioSenic S.A. | 543 Thousand EUR | -37420.258% |
| Celyad Oncology SA | 33 Thousand EUR | -617278.788% |
| DBV Technologies S.A. | 4.15 Million EUR | -4797.956% |
| Genfit S.A. | 28.22 Million EUR | -621.85% |
| GeNeuro SA | -293.8 Thousand EUR | 69444.792% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -10117.402% |
| Innate Pharma S.A. | -4.12 Million EUR | 5043.824% |
| Inventiva S.A. | 17.5 Million EUR | -1064.2% |
| MaaT Pharma SA | 1.65 Million EUR | -12210.272% |
| MedinCell S.A. | 9.28 Million EUR | -2093.529% |
| Nanobiotix S.A. | 36.2 Million EUR | -462.68% |
| Onward Medical N.V. | -14.81 Million EUR | 1474.916% |
| Oryzon Genomics S.A. | 13.94 Million EUR | -1360.684% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -9048.406% |
| Oxurion NV | 104 Thousand EUR | -195799.038% |
| Pharming Group N.V. | 220.1 Million EUR | 7.437% |
| Poxel S.A. | 1000.00 EUR | -20373400.0% |
| GenSight Biologics S.A. | 3 Million EUR | -6691.167% |
| Transgene SA | -28.4 Million EUR | 817.276% |
| Financière de Tubize SA | -2.02 Million EUR | 10138.259% |
| UCB SA | 3.34 Billion EUR | 93.904% |
| Valneva SE | 52.83 Million EUR | -285.592% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 6682.714% |